.
MergerLinks Header Logo

New Deal


Announced

Invitae to acquire Ciitizen for $325m.

Financials

Edit Data
Transaction Value£234m
Consideration TypeCash, Ordinary Shares
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Majority

Friendly

Pending

United States

health company

Single Bidder

Domestic

Health Care Services

Acquisition

Private

Synopsis

Edit

Invitae, a medical genetics company, agreed to acquire Ciitizen, a patient-centric consumer health tech company, for $325m. "Invitae is relentlessly pursuing a day when genetics is used routinely to improve healthcare for billions of people around the globe. We believe combining Ciitizen's state-of-the-art, transparent and patient-consented platform with our technologies and services will accelerate our evolution into a genome information company that informs healthcare throughout one's life. This would give us the ability to engage patients, create an innovative patient-centered data ecosystem and deliver better outcomes for everyone. Invitae views the acquisition of Ciitizen as an important part of its strategy to be the industry leader across the genetic testing, software and health information technology spaces," Sean George, Co-Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US